RxDoctor Payments Data

Alexander Kiotis, DO

Family Medicine · Plymouth Meeting, PANPI 1093732752

Payments from drug & device makers

$1,681in general payments, 2019–2025

Across 35 payments — averaging $48.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Acadia Pharmaceuticals Inc$417
  • Sunovion Pharmaceuticals Inc.$356
  • Otsuka America Pharmaceutical, Inc.$211
  • Avanir Pharmaceuticals, Inc.$132
  • AstraZeneca$125
  • Sun Pharmaceutical Industries Inc.$123
  • plus $318 from 5 others

What the payments were for

  • Food & beverage$1,681100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,681 in reported general payments places this provider in the 75th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$280,557
Medicare patients
685
Services billed
2,659

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban236$109,406
IngrezzaValbenazine Tosylate26$79,153
EnbrelEtanercept13$77,103
TrulicityDulaglutide73$38,707
MyrbetriqMirabegron58$25,095
XareltoRivaroxaban45$21,698
EntrestoSacubitril/Valsartan44$20,243
JardianceEmpagliflozin58$18,865
Trelegy ElliptaFluticasone/Umeclidin/Vilanter27$16,566
Midodrine Hcl76$8,443
Lacosamide41$8,026
Potassium Chloride234$7,036
LumiganBimatoprost26$6,905
Atorvastatin Calcium504$6,776
Repaglinide54$4,988

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$20$79,15326 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Plymouth Meeting

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →